ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 764–767 0066-4804/01/$04.00⫹0 DOI: 10.1128/AAC.45.3.764–767.2001 Copyright © 2001, American Society for Microbiology. All Rights Reserved.
Vol. 45, No. 3
Activities of Linezolid against Rapidly Growing Mycobacteria R. J. WALLACE, JR.,* B. A. BROWN-ELLIOTT, S. C. WARD, C. J. CRIST, L. B. MANN, AND R. W. WILSON Department of Microbiology, University of Texas Health Center, Tyler, Texas Received 5 September 2000/Returned for modification 8 November 2000/Accepted 4 December 2000
Linezolid is an oxazolidinone available as an oral drug which has activity against most gram-positive bacteria. However, few species of the genus Mycobacterium have been studied. We tested 249 clinical isolates and 10 reference strains of rapidly growing mycobacteria for susceptibility to linezolid by broth microdilution. Clinical species included the Mycobacterium fortuitum group (n ⴝ 74), M. abscessus (n ⴝ 98), M. chelonae (n ⴝ 50), M. mucogenicum (n ⴝ 10), and M. fortuitum third biovariant complex (10). The modal MIC for M. mucogenicum was 1.0 g/ml, and the MIC at which 90% of the isolates tested are inhibited (MIC90) was 4 g/ml; the modal MIC for the M. fortuitum group was 4 g/ml, and the MIC90 was 16 g/ml; the modal MIC for the M. fortuitum third biovariant complex was 4 g/ml, and the MIC90 was 8 g/ml; the modal MIC for M. chelonae was 8 g/ml, and the MIC90 was 16 g/ml; and the modal MIC for M. abscessus was 32 g/ml, and the MIC90 was 64 g/ml. Based on peak levels of linezolid in serum of 15 to 20 g/ml, we propose the following broth MIC breakpoints for these species: susceptible, < 8 g/ml; moderately susceptible, 16 g/ml; and resistant, >32 g/ml). These studies demonstrate the excellent potential of linezolid for therapy of rapidly growing mycobacteria. bacterium fortuitum, M. chelonae, and M. abscessus (24), were studied. (This work was presented in part as an abstract at the 100th General Meeting of the American Society for Microbiology, Los Angeles, Calif.)
Treatment of infections due to nontuberculous mycobacteria remains difficult, in part because they are resistant to many of the first-line tuberculosis agents and in part because so few other agents are available for therapy (21). The oxazolidinones are one of several new classes of agents active against grampositive bacteria (4, 8, 11; M. C. Birmingham, G. S. Zimmer, B. Hafkin, W. M. Todd, T. Leach, D. H. Batts, S. M. Flavin, C. R. Rayner, K. E. Welch, P. F. Smith, J. D. Root, N. E. Wilks, and J. J. Schentag, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1098, 1999) which have the potential for activity against nontuberculous mycobacteria, including the rapidly growing mycobacteria (6; M. Wu, P. Aralor, K. Nash, L. E. Bermudez, C. B. Inderlied, and L. S. Young, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. E-143, 1998; L. E. Bermudez, Abstr. Int. Conf. Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinone, abstr. 03.16, 2000). We chose to study linezolid, which along with eperezolid is the first of the oxazolidinones to reach clinical testing (4; M. C. Birmingham et al., 39th ICAAC) Linezolid offers special promise, as it is a twice-daily oral drug which is 100% bioavailable (Zyvox package insert, 2000 [Pharmacia & Upjohn, Inc.]; also see reference 8) and appears to be well tolerated (8; N. E. Wilks, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1763, 1999), important features of therapeutic drugs to be used against nontuberculous mycobacteria which cause chronic infections and require long-term therapy (often 6 months or longer) (21). The activities of linezolid against a large number of clinical isolates of rapidly growing mycobacteria, including the common disease-producing species Myco-
MATERIALS AND METHODS Organisms. We tested 249 clinical isolates of rapidly growing mycobacteria belonging to seven taxonomic groups which had been submitted for susceptibility testing to the Mycobacteria/Nocardia Laboratory at the University of Texas Health Center between 1998 and 2000. Organisms were identified to the species level by PCR restriction fragment length polymorphism analysis of the 439-bp (Telenti) segment of the 65-kDa hsp gene (14, 17) or by pattern of drug susceptibility to approximately 15 other drugs, including aminoglycosides, beta-lactams, and quinolones (2). The test species used and the number of clinical test isolates (in parentheses) were as follows: M. fortuitum group without separation into M. fortuitum, M. peregrinum, or M. fortuitum third biovariant complex (n ⫽ 74); M. fortuitum third biovariant complex (n ⫽ 10 [with five each being sorbitol positive and sorbitol negative]); M. abscessus (n ⫽ 98); M. chelonae (n ⫽ 50); M. mucogenicum (n⫽10); M. immunogenum (n⫽4) (see reference 25; and M. smegmatis group (n⫽3). Four reference strains obtained or submitted by our laboratory to the American Type Culture Collection (Manassas, Va.) were also tested. These included M. peregrinum ATCC 700686, M. fortuitum ATCC 6841T, M. chelonae ATCC 35752T, and M. abscessus ATCC 19977T. Susceptibility testing. Susceptibility testing utilized serial twofold broth microdilution in cation supplemented Mueller-Hinton broth as previously described (2). Susceptibilities to linezolid were read after incubation at 30°C in room air for 3 days. The endpoint was complete (100%) inhibition of visible growth. Quality control. Quality control was performed using Staphylococcus aureus ATCC 29213. The acceptable range of inhibition for this strain was 1 to 4 g/ml (18 to 24 h of incubation) (linezolid package insert, 2000 [Pharmacia & Upjohn, Inc.]). M. peregrinum ATCC 700686 was also tested as a rapid-grower control as recently recommended (26). Both were used initially after preparation of the MIC panels and then weekly.
RESULTS Susceptibility testing. Susceptibility to linezolid was determined for 249 clinical isolates of rapidly growing mycobacteria belonging to seven taxonomic groups. In general, a unimodal distribution of MICs was seen for the common species or
* Corresponding author. Mailing address: The University of Texas Health Center, Department of Microbiology, 11937 U.S. Hwy. 271, Tyler, TX 75708. Phone: (903) 877-7680. Fax: (903) 877-7652. E-mail:
[email protected]. 764
VOL. 45, 2001
LINEZOLID AND RAPIDLY GROWING MYCOBACTERIA
765
TABLE 1. Susceptibility of 249 clinical isolates of seven species or taxa of rapidly growing mycobacteria to linezolid as determined by broth microdilution Species
M. M. M. M. M. M. M. a b
fortuitum groupa fortuitum third biovariant complex abscessus chelonae mucogenicum smegmatis groupb immunogenum
No. (cumulative %) of isolates inhibited by MIC (g/ml) of: 0.25
ⱕ0.5
1
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 2 (2) 0 (0) 2 (20) 1 (33) 0 (0)
4 (5) 0 (0) 0 (2) 1 (2) 4 (60) 0 (33) 0 (0)
2
4
8
15 (26) 26 (61) 19 (86) 1 (10) 6 (70) 3 (100) 1 (3) 6 (9) 14 (23) 0 (0) 5 (12) 21 (54) 1 (70) 2 (90) 1 (100) 1 (67) 1 (100) 0 0 (0) 0 (0) 0 (0)
16
32
64
7 (96) 3 (100) 0 (100) 0 0 0 24 (48) 39 (88) 10 (98) 20 (94) 2 (98) 1 (100) 0 0 0 0 0 0 2 (50) 2 (100) 0
ⱖ128
No. of isolates tested
0 0 2 (100) 0 (100) 0 0 0
74 10 98 50 10 3 4
Includes M. fortuitum, M. peregrinum, and M. fortuitum third biovariant complex. Includes M. goodii and M. smegmatis sensu stricto.
groups, with ⬎90% of MICs within two dilutions of the mode. Of the common pathogenic species, the drug was most active against isolates of M. mucogenicum and the M. fortuitum group, including both members of M. fortuitum third biovariant complex. Of the M. mucogenicum isolates, 6 of 10 (60%) were inhibited by linezolid at concentrations of 1 g/ml, and 100% were inhibited by linezolid at 8 g/ml. For M. fortuitum, 45 of 74 (61%) of the test isolates were inhibited by linezolid at concentrations of 4 g/ml or less, and 96% were inhibited by linezolid at concentrations 16 g/ml or less, with a mode of 4 g/ml. For M. fortuitum third biovariant complex, all 10 isolates were within one dilution of the mode of 4 g/ml (Tables 1 and 2). The drug was also active when tested against isolates of M. chelonae. Twenty-seven of 50 (54%) isolates were inhibited by linezolid at concentrations of 8 g/ml or less, and 47 of 50 (94%) were inhibited by linezolid at 16 g/ml or less. The mode for M. chelonae was 8 g/ml, with 41 of 50 isolates (82%) having an MIC of either 8 or 16 g/ml (Tables 1 and 2). Isolates of M. abscessus were the least susceptible to linezolid of the three common species of rapidly growing mycobacteria. With testing of 98 isolates and 100% growth inhibition, only 23 of 98 (23%) isolates were inhibited by linezolid at concentrations of 8 g/ml or less, and only 47 of 98 (48%) were inhibited by linezolid at 16 g/ml (Tables 1 and 2). The linezolid MIC for M. fortuitum ATCC 6841T was 8 g/ml, that for M. chelonae ATCC 35752T was 1 g/ml, and that for M. abscessus ATCC 19977T was 64 g/ml.
Quality control. The S. aureus control strain was within the expected MIC range. The strain of M. peregrinum ATCC 700686 recommended as an MIC control strain (26) was tested 54 times. The modal MIC was 4g/ml (31 values), with 11 values at 2 g/ml and 9 values at 8 g/ml. A total of 51 of 54 (94%) values were within one dilution of the mode, and 100% were within two dilutions. DISCUSSION The manufacturer of linezolid has proposed ⱖ8 g/ml as the resistance breakpoint of linezolid for Enterococcus spp. (package insert for Zyvox, 2000 [Pharmacia & Upjohn Inc.]). For Staphylococcus species the susceptibility breakpoint is ⱕ4 g/ ml, and for Streptococcus spp. it is ⱕ2 g/ml. No resistance breakpoints were given for these two groups because of the absence of isolates for which the linezolid MICs were ⬎4 g/ml and hence no experience with isolates such as these rapidly growing mycobacteria which have higher MICs. Peak levels of the drug in serum after oral doses of 600 mg twice a day (mean ⫾ standard deviation are 21.2 ⫾ 5.8 g/ml, with a half-life of 5.4 h (package insert for Zyvox, 2000 [Pharmacia & Upjohn Inc.]), suggesting that 16 g/ml might be an acceptable intermediate value for other organisms. Pending clinical experience, we propose the following breakpoints for these mycobacterial species: susceptible, ⱕ8 g/ml; intermediate, 16 g/ ml; and resistant, ⱖ32 g/ml. Drug treatment of rapidly growing mycobacteria has been
TABLE 2. Susceptibility of 249 isolates of rapidly growing mycobacteria to linezolid as determined by broth microdilution Organism
M. M. M. M. M. M. M.
fortuitum groupa fortuitum third biovariant complex abscessus chelonae mucogenicum smegmatis groupb immunogenum
Range or total a b c
MIC (g/ml)c
No. of isolates tested
Range
50%
90%
Mode
74 10 98 50 10 3 4
1–32 2–8 0.5–128 1–64 0.5–8 0.5–4 16–32
4
16 8 64 16 4 4 32
4
249
0.5–128
Includes M. fortuitum, M. peregrinum, and M. fortuitum third biovariant complex. Includes M. goodii and M. smegmatis sensu stricto. 50% and 90%, MICs at which 50 and 90% of isolates are inhibited, respectively.
32 8
1–32
4–64
32 8
0.5–32
% Susceptible or intermediate (MIC ⱕ16 g/ml)
96 100 48 94 100 100 50 48–100
766
WALLACE ET AL.
severely limited by the small number of available drugs with activity at clinically achievable levels in tissue (blood), especially oral drugs (15, 21, 24). For M. chelonae and M. abscessus, clarithromycin (and the other macrolides) is the only oral agent active against all untreated strains (3, 15, 18, 19, 22). Acquired mutational resistance is a concern with monotherapy with this drug, and several mutations have been described which were associated with marked increases in macrolide MICs and clinical treatment failure (16, 22). Linezolid offers great promise as a macrolide companion drug for isolates of M. chelonae, as 94% of all isolates tested were inhibited by this drug at concentrations of ⱕ16 g/ml, with a mode of 8 g/ml, including strains with acquired clarithromycin resistance (data not shown). The MICs were higher for M. abscessus than for M. chelonae, but 48% of these isolates were inhibited by linezolid at concentrations of 16 g/ml. Chronic lung disease in the setting of bronchiectasis (nodular bronchiectasis in elderly women or young adolescents with cystic fibrosis) is one of the more common forms of clinical disease due to M. abscessus (5, 9, 10, 12, 24) and is currently incurable with drugs alone (5, 10, 12, 21). Despite these MICs, linezolid is one of the few drugs to offer promise for treatment of this disease. The third common pathogenic rapidly growing mycobacterial species (group) to be tested was the M. fortuitum group. This group includes M. fortuitum, M. peregrinum, M. fortuitum third biovariant (sorbitol positive), and M. fortuitum third biovariant (sorbitol negative) (23). These species and taxa have very similar drug susceptibilities (15, 18, 20). Most or all untreated strains are susceptible to the newer quinolones and sulfamethoxazole (15, 18), although acquired mutational resistance to the newer quinolones (18) limits the use of this class of drugs as monotherapy. Some but not all isolates of M. fortuitum are also susceptible to doxycycline and minocycline (42%) (15) and clarithromycin (3). Isolates of M. peregrinum and M. fortuitum third biovariant sorbitol negative are all susceptible to clarithromycin (MIC, ⱕ4 g/ml) while all isolates of M. fortuitum third biovariant (sorbitol positive) are clarithromycin resistant (MICs ⬎ 4 g/ml) (3). For the M. fortuitum group, 61% of isolates were inhibited by 4 g of linezolid per ml, and 86% were inhibited by 8 g of linezolid per ml. Thus, linezolid offers the promise of an additional oral drug which could be used for all isolates of this species or group. The MIC endpoint used in this study was 100% inhibition of visible growth, an endpoint suggested by Pharmacia & Upjohn, Inc. Instructions with the recently released linezolid E-test (AB Biodisk), however, are to use an 80% growth inhibition endpoint rather than 100%. E-test MIC data for clinical isolates in the present study were not available because the 80% growth inhibition endpoint was not studied. A trailing endpoint appeared to be minimal with these groups or species by broth microdilution, as use of 80% inhibition compared to 100% inhibition only decreased the MICs by an average of one dilution (data not shown). Only clinical trials will determine if the suggested broth MIC breakpoints for these mycobacteria (susceptible ⱕ8 g/ml, moderately susceptible ⫽ 16 g/ml, resistance ⱖ32 g/ml) is appropriate or correct. Acquired resistance to linezolid among gram-positive bacteria, primarily Enterococcus spp., has been described (P. Linden, D. Parkinson, A. W. Pasculle, M. Birmingham, G.
ANTIMICROB. AGENTS CHEMOTHER.
Zurenko, B. Hafkin, and D. Batts, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1105, 1999; T. K. Chowdhry, S. H. Marshall, C. J. Donskey, R. A. Salata, and L. B. Rice, Abstr. 100th Meet. Am. Soc. Microbiol. abstr. A63, 2000; S. M. Swaney, D. Shinabarger, R. Schaadt, J. Bock, J. Slightom, and G. Zurenko, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-104, 1998). These cases have defined point mutations involving the rRNA gene. This is a point of concern with strains of M. chelonae and M. abscessus, which have only a single copy of the ribosomal operon (1, 7, 22) and for which single point mutations in the ribosomal gene following monotherapy would likely result in drug resistance. Resistance from such mutational changes in the ribosomes of these two species has been described with clarithromycin (A2058 or A2059 in the 16S rRNA gene) (16, 22) and amikacin (A1408 in the 23S r-RNA gene) (13). Previous studies have shown that mutational ribosomal resistance with the macrolides is a problem only in the setting of disseminated cutaneous disease or pulmonary disease, but not with localized wound infections. Thus, linezolid should be used in combination therapy whenever possible with treatment of M. chelonae and M. abscessus, in the setting of disseminated or pulmonary disease. There is less concern with isolates of the M. fortuitum group, as they have two copies of the ribosomal operon (1, 7) and heterologous resistance with amikacin is recessive. A serious limitation on therapy of disease due to these organisms is the cost of the drug, which is approximately $45 for a single 600-mg tablet, with a daily dosing schedule of 600 mg twice daily. This likely will mean that only patients in desperate clinical straits or in whom other drugs have failed will receive treatment, which is a difficult situation in which to determine clinical efficacy. At present no phase four clinical trials or compassionate trials of treatment of mycobacterial disease with linezolid are planned or are under way in the United States, although the drug was available on a compassionate basis prior to approval by the Food and Drug Administration. Other oxazolidinones are in trial or under consideration (R. C. Gadwood, L. M. Thomasco, E. A. Weaver, G. E. Zurenko, and C. W. Ford, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 571, 1999). Hopefully these will come with a lower price tag, which will allow greater investigation of this very promising drug for disease caused by rapidly growing mycobacteria. ACKNOWLEDGMENTS We thank Joanne Woodring for her excellent clerical assistance. This study was supported in part by a grant from Pharmacia and Upjohn, Inc. REFERENCES 1. Bercovier, H., O. Kafri, and S. Sela. 1986. Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. Biochem. Biophys. Res. Commun. 136:1136–1141. 2. Brown, B. A., J. M. Swenson, and R. J. Wallace, Jr. 1992. Broth microdilution MIC test for rapidly growing mycobacteria, p. 5.11.1. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C. 3. Brown, B. A., R. J. Wallace, Jr., G. O. Onyi, V. De Rosas, and R. J. Wallace III. 1992. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob. Agents Chemother. 36:180–184. 4. Chien, J. W., M. L. Kucia, and R. A. Salata. 2000. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30:146–151.
VOL. 45, 2001 5. Cullen, A. R., C. L. Cannon, E. J. Mark, and A. A. Colin. 2000. Mycobacterium abscessus infection in cystic fibrosis. Am. J. Respir. Crit. Care Med. 161:641–645. 6. Cynamon, M. H., S. P. Klemens, C. A. Sharpe, and S. Chase. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43:1189–1191. 7. Domenech, P., M. C. Menendez, and M. J. Garcia. 1994. Restriction fragment length polymorphisms of 16S rRNA genes in the differentiation of fast-growing mycobacterial species. FEMS Microbiol. Lett. 16:19–24. 8. Dresser, L. D., and M. J. Rybak. 1998. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18:456–462. 9. Griffith, D. E., W. M. Girard, and R. J. Wallace, Jr. 1993. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am. Rev. Respir. Dis. 147:1271–1278. 10. Kennedy, T. P., and D. J. Weber. 1994. Nontuberculous mycobacteria: an underappreciated cause of geriatric lung disease. Am. J. Respir. Crit. Care Med. 149:1654–1658. 11. Noskin, G. A., F. Siddiqui, V. Stosor, D. Hacek, and L. R. Peterson. 1999. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 43:2059–2062. 12. Olivier, K. N., J. R. Yankaskas, and M. R. Knowles. 1996. Non-tuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin. Respir. Infect. 11:272–284. 13. Prammananan, T., P. Sander, B. A. Brown, K. Frischkorn, G. O. Onyi, Y. Zhang, E. C. Bo ¨ttger, and R. J. Wallace, Jr. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177:1573–1581. 14. Steingrube, V. A., J. L. Gibson, B. A. Brown, Y. Zhang, R. W. Wilson, M. Rajagopalan, and R. J. Wallace, Jr. 1995. PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria. J. Clin. Microbiol. 33:149–153. 15. Swenson, J. M., R. J. Wallace, Jr., V. A. Silcox, and C. Thornsberry. 1985. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob. Agents Chemother. 28:807–811. 16. Tebas, P., F. Sultan F, R. J. Wallace, Jr., and V. Fraser. 1995. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin. Infect. Dis. 20:443–444. 17. Telenti, A., F. Marchesi, M. Balz, F. Bally, E. C. Bo¨ttger, and T. Bodmer.
LINEZOLID AND RAPIDLY GROWING MYCOBACTERIA
18.
19.
20.
21.
22.
23. 24. 25.
26.
767
1993. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J. Clin. Microbiol. 31:175– 178. Wallace, R. J., Jr., G. Bedsole, G. Sumter, C. V. Sanders, L. C. Steele, B. A. Brown, J. Smith, and D. R. Graham. 1990. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob. Agents Chemother. 34:65–70. Wallace, R. J., Jr., B. A. Brown, and G. O. Onyi. 1992. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J. Infect. Dis. 166:405–412. Wallace, R. J., Jr., B. A. Brown, V. A. Silcox, M. Tsukamura, D. R. Nash, L. C. Steele, V. A. Steingrube, J. Smith, G. Sumter, Y. Zhang, and Z. Blacklock. 1991. Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum. J. Infect. Dis. 163:598–603. Wallace, R. J., Jr., J. L. Cook, J. Glassroth, D. E. Griffith, K. N. Olivier, and F. Gordin. 1997. American Thoracic Society statement: diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. Respir. Crit. Care Med. 156:S1–S25. Wallace, R. J., Jr., A. Meier, B. A. Brown, Y. Zhang, P. Sander, G. O. Onyi, and E. C. Bo ¨ttger. 1996. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40:1676–1681. Wallace, R. J., Jr., V. Silcox, and B. A. Brown. 1994. Taxonomy of rapidly growing mycobacteria. Clin. Infect. Dis. 18:121–122. Wallace, R. J., Jr., J. M. Swenson, V. A. Silcox, R. C. Good, J. A. Tschen, and M. S. Stone. 1983. Spectrum of disease due to rapidly growing mycobacteria. Rev. Infect. Dis. 5:657–679. Wilson, R. W., V. A. Steingrube, E. C. Bo ¨ttger, B. Springer, B. A. BrownElliott, V. Vincent, K. C. Jost, Jr., Y. Zhang, M. J. Garcia, S. H. Chiu, G. O. Onyi, H. Rossmoore, D. R. Nash, and R. J. Wallace, Jr. A new mycobacterial species related to Mycobacterium abscessus associated with clinical disease, pseudo-outbreaks, and contaminated metalworking fluids: Mycobacterium immunogenum sp. nov.—an international cooperative study on mycobacterial taxonomy. Int. J. Syst. Evol. Microbiol., in press. Woods, G. L., J. S. Bergmann, F. G. Witebsky, G. A. Fahle, A. Wanger, B. Boulet, M. Plaunt, B. A. Brown, and R. J. Wallace, Jr. 1999. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 37:1676–1682.
